LLS Therapy Acceleration Program® (TAP) Supported Stemline’s Key Clinical Studies in BPDCN

The Leukemia & Lymphoma Society Therapy Acceleration Program® (LLS TAP) is one of the pioneers of venture philanthropy. Hear what the SVP of Corporate & Business Development of Stemline Therapeutics has to say about TAP and the value created for his company beyond the funding amount. LLS TAP partnered with Stemline in 2013 to support key clinical studies for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN).

On December 21, 2018 the FDA approved Elzonris® (tagraxofusp-erzs) infusion for the treatment of BPDCN in adults and in pediatric patients. Elzonris is the first approved therapy for BPDCN, a rare blood cancer.